Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The HRD Decision-Which PARP Inhibitor to Use for Whom and When.

Clinical cancer research : an official journal of the American Association for Cancer Research - 1 Dec 2017

Kohn Elise C, Lee Jung-Min, Ivy S Percy

Abstract excerpt

Rucaparib, a polyADPribose polymerase inhibitor (PARPi), was approved recently for use in women with high-grade serous ovarian cancer (HGSOC). It is now one of three approved PARPi for use in recurrent ovarian cancer, a family of agents that has changed the HGSOC treatment landscape and outcome. Clin Cancer Res; 23(23); 7155-7. ©2017 AACRSee related article by Balasubramaniam et al., p. 7165.

Topics

Join the communities discussing this publication.

Indoles
Mutation
Neoplasm Recurrence, Local
Ovarian Neoplasms
Poly(ADP-ribose) Polymerase Inhibitors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Open in PubMed Open full text

Identifiers

PMID: 28974545
DOI: 10.1158/1078-0432.CCR-17-2186
PMCID: PMC5712252

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The HRD Decision-Which PARP Inhibitor to Use for Whom and When.PMID 28974545Read ↗

Poly (ADP-Ribose) Polymerase Inhibitors: Recent Advances and Future DevelopmentSemantic proximity Read ↗

PARP Inhibitors in the Management of Ovarian Cancer: ASCO GuidelineSemantic proximity Read ↗

PARP Inhibitors in Ovarian Cancer: A ReviewSemantic proximity Read ↗

PARP Inhibitors for Ovarian Cancer: Current Indications, Future Combinations, and Novel Assets in Development to Target DNA Damage RepairSemantic proximity Read ↗

Overall Survival and the Evolving Benefit-Risk Assessment for Poly (ADP-ribose) Polymerase Inhibitors in Advanced Ovarian CancerSemantic proximity Read ↗

First-line PARP inhibition in ovarian cancer - standard of care for all?Semantic proximity Read ↗

PARP Inhibitors in Ovarian Cancer: The Route to “Ithaca”Semantic proximity Read ↗

PARP Inhibitors for Cancer Therapy.Semantic proximity Read ↗

PARP-inhibitors in epithelial ovarian cancer: Actual positioning and future expectationsSemantic proximity Read ↗

PARP inhibitors: a tsunami of indications in different malignancies.Semantic proximity Read ↗

A Pan-Canadian Consensus Statement on First-Line PARP Inhibitor Maintenance for Advanced, High-Grade Serous and Endometrioid Tubal, Ovarian, and Primary Peritoneal Cancers.Semantic proximity Read ↗

Rucaparib in ovarian cancer: extending the use of PARP inhibitors in the recurrent disease.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.